{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:tadalafil",
  "owner": "cardio",
  "kind": "drug",
  "slug": "tadalafil",
  "name": "Tadalafil",
  "aliases": [
    "ADCIRCA",
    "ALYQ"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Tadalafil, in the forms sold as Adcirca and Alyq for pulmonary arterial hypertension (PAH), is a phosphodiesterase 5 (PDE5) inhibitor. The US labels of both products list treating PAH (WHO Group 1) to improve exercise ability. This page covers the pulmonary arterial hypertension use. Tadalafil also has a separate US label for erectile dysfunction and for benign prostatic hyperplasia, which this page does not describe. The label says tadalafil inhibits PDE5, the enzyme that breaks down cyclic guanosine monophosphate.",
  "summary_technical": "RxNorm ingredient 358263; UNII 742SXX0ICT. MeSH D000068581 is Tadalafil, with Cialis among its entry terms (a lookup on 2026-11-18, hash only), and carries no scope note, so it is recorded as an exact match for identity only. RxClass lists the established pharmacologic class Phosphodiesterase 5 Inhibitor, so the record is filed under the PDE5 inhibitor page for pulmonary hypertension. The labels read are Adcirca (United Therapeutics Corporation, NDA022332, effective 2025-12-15 in openFDA) and Alyq (Teva Pharmaceuticals, Inc., ANDA216932, effective 2023-04-01). The Cialis label (NDA021368, effective 2026-06-03) was read only for its indication sentences. Drugs@FDA also holds fixed combinations with another ingredient, which a single-ingredient match would not include; they were not read. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "358263",
      "normalized_value": "358263",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "742SXX0ICT",
      "normalized_value": "742SXX0ICT",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "mesh",
      "value": "D000068581",
      "normalized_value": "D000068581",
      "match": "exact",
      "version": "id.nlm.nih.gov linked data, retrieved 2026-11-18",
      "label": "Tadalafil",
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "blood-vessels",
        "heart"
      ],
      "condition-area": [
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says tadalafil is an inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP)."
  },
  "content_digest": "20c74684d9a65f914c36826b968c3e21da91299b721d5eeb9c8023d1c33fa923",
  "review": {
    "content_digest": "20c74684d9a65f914c36826b968c3e21da91299b721d5eeb9c8023d1c33fa923",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-adcirca-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:tadalafil",
      "category": "descriptive",
      "statement": "The US label of Adcirca (tadalafil, United Therapeutics Corporation, application NDA022332; the version dated 2025-12-15 in openFDA) calls the medicine a phosphodiesterase 5 (PDE5) inhibitor. It lists treating pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. The US label of Alyq (tadalafil tablets, Teva Pharmaceuticals, Inc., application ANDA216932; the version dated 2023-04-01 in openFDA) lists the same use.",
      "context": {
        "id": "cardio:ctx-fda-adcirca-label-us",
        "label": "Patients with pulmonary arterial hypertension, as described in the US labels of Adcirca and Alyq",
        "recipient": "unknown",
        "population": "Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the labels state. The passage read gives no age range.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Not stated in the passages read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the labels state. The passage read gives no age range."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim is tied to the two pulmonary arterial hypertension labels named. The substance also has separate labels for other uses, which are not recorded here. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA022332.",
          "snapshot": {
            "id": "cardio:openfda-label-adcirca-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:37Z",
            "content_hash": "842c342248c8be4ffaa382bf9f35083a88a1f4e85dc21f70e1ccd15ee9129532",
            "source_effective_date": "2025-12-15",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-adcirca",
            "source_type": "regulator",
            "title": "openFDA drug label record for Adcirca (tadalafil tablets), United Therapeutics Corporation label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22ff61b237-be8e-461b-8114-78c52a8ad0ae%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id ff61b237-be8e-461b-8114-78c52a8ad0ae (manufacturer United Therapeutics Corporation, application NDA022332), returned on 2026-11-18. The label text is dated 2025-12-15 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-adcirca.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20251215.",
          "snapshot": {
            "id": "cardio:openfda-label-adcirca-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:37Z",
            "content_hash": "842c342248c8be4ffaa382bf9f35083a88a1f4e85dc21f70e1ccd15ee9129532",
            "source_effective_date": "2025-12-15",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-adcirca",
            "source_type": "regulator",
            "title": "openFDA drug label record for Adcirca (tadalafil tablets), United Therapeutics Corporation label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22ff61b237-be8e-461b-8114-78c52a8ad0ae%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id ff61b237-be8e-461b-8114-78c52a8ad0ae (manufacturer United Therapeutics Corporation, application NDA022332), returned on 2026-11-18. The label text is dated 2025-12-15 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-adcirca.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K30-TAD-LB-04).",
          "snapshot": {
            "id": "cardio:openfda-label-adcirca-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:37Z",
            "content_hash": "842c342248c8be4ffaa382bf9f35083a88a1f4e85dc21f70e1ccd15ee9129532",
            "source_effective_date": "2025-12-15",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-adcirca",
            "source_type": "regulator",
            "title": "openFDA drug label record for Adcirca (tadalafil tablets), United Therapeutics Corporation label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22ff61b237-be8e-461b-8114-78c52a8ad0ae%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id ff61b237-be8e-461b-8114-78c52a8ad0ae (manufacturer United Therapeutics Corporation, application NDA022332), returned on 2026-11-18. The label text is dated 2025-12-15 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-adcirca.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the Alyq label read, ANDA216932.",
          "snapshot": {
            "id": "cardio:openfda-label-alyq-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:47Z",
            "content_hash": "47997986bf19175c15349dd70340939659f81639a533059b7758bd2fdb5c7cff",
            "source_effective_date": "2023-04-01",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-alyq",
            "source_type": "regulator",
            "title": "openFDA drug label record for Alyq (tadalafil tablets, USP), Teva Pharmaceuticals, Inc. label: indications",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%222faa7a55-3054-456b-8465-6ea6dc1c0aa9%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 2faa7a55-3054-456b-8465-6ea6dc1c0aa9 (manufacturer Teva Pharmaceuticals, Inc., application ANDA216932), returned on 2026-11-18. The label text is dated 2023-04-01 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-2faa7a55-3054-456b-8465-6ea6dc1c0aa9.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the Alyq label text read, 20230401.",
          "snapshot": {
            "id": "cardio:openfda-label-alyq-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:47Z",
            "content_hash": "47997986bf19175c15349dd70340939659f81639a533059b7758bd2fdb5c7cff",
            "source_effective_date": "2023-04-01",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-alyq",
            "source_type": "regulator",
            "title": "openFDA drug label record for Alyq (tadalafil tablets, USP), Teva Pharmaceuticals, Inc. label: indications",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%222faa7a55-3054-456b-8465-6ea6dc1c0aa9%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 2faa7a55-3054-456b-8465-6ea6dc1c0aa9 (manufacturer Teva Pharmaceuticals, Inc., application ANDA216932), returned on 2026-11-18. The label text is dated 2023-04-01 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-2faa7a55-3054-456b-8465-6ea6dc1c0aa9.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K30-TAD-AL-03).",
          "snapshot": {
            "id": "cardio:openfda-label-alyq-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:47Z",
            "content_hash": "47997986bf19175c15349dd70340939659f81639a533059b7758bd2fdb5c7cff",
            "source_effective_date": "2023-04-01",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-alyq",
            "source_type": "regulator",
            "title": "openFDA drug label record for Alyq (tadalafil tablets, USP), Teva Pharmaceuticals, Inc. label: indications",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%222faa7a55-3054-456b-8465-6ea6dc1c0aa9%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 2faa7a55-3054-456b-8465-6ea6dc1c0aa9 (manufacturer Teva Pharmaceuticals, Inc., application ANDA216932), returned on 2026-11-18. The label text is dated 2023-04-01 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-2faa7a55-3054-456b-8465-6ea6dc1c0aa9.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "520d40226d027a73be6cb4ed291ade0aa2f47fcbc197b353ead1caf7f99ff2e3",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-adcirca-label-indications.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Tadalafil is a phosphodiesterase 5 inhibitor (FDA established pharmacologic class in RxClass)",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:pde5-inhibitors-for-pulmonary-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-358263-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA labels for Adcirca and Alyq list pulmonary arterial hypertension (WHO Group 1), to improve exercise ability, as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-adcirca-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": [
      {
        "predicate": "related_to",
        "label": "Related to",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:ambrisentan",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "Related to",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:endothelin-receptor-antagonists",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "Related to",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:macitentan",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ]
  },
  "page_path": "drugs/tadalafil/",
  "context_path": "api/v1/context/cardio--tadalafil.md"
}
